Inadomi JM - Search Results

1

The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis.

Omidvari AH, Hazelton WD, Lauren BN, Naber SK, Lee M, Ali A, Seguin C, Kong CY, Richmond E, Rubenstein JH, Luebeck GE, Inadomi JM, Hur C, Lansdorp-Vogelaar I. Omidvari AH, et al. Among authors: inadomi jm. Gastroenterology. 2021 Aug;161(2):487-494.e4. doi: 10.1053/j.gastro.2021.05.003. Epub 2021 May 8. Gastroenterology. 2021. PMID: 33974935 Free PMC article.

2

Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis.

Inadomi J, Sonnenberg A. Inadomi J, et al. Gastroenterology. 1997 Oct;113(4):1289-94. doi: 10.1053/gast.1997.v113.pm9322524. Gastroenterology. 1997. PMID: 9322524

3

Empiric beta-blockers for the prophylaxis of variceal hemorrhage: cost effective or clinically applicable?

Rubenstein JH, Inadomi JM. Rubenstein JH, et al. Among authors: inadomi jm. Hepatology. 2003 Feb;37(2):249-52. doi: 10.1053/jhep.2003.50089. Hepatology. 2003. PMID: 12540773 Free article. Review. No abstract available.

4

Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.

Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Inadomi JM, et al. Ann Intern Med. 2003 Feb 4;138(3):176-86. doi: 10.7326/0003-4819-138-3-200302040-00009. Ann Intern Med. 2003. PMID: 12558356

5

Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis.

Inadomi JM. Inadomi JM. Scand J Gastroenterol Suppl. 2003;(237):17-21. doi: 10.1080/00855910310001430. Scand J Gastroenterol Suppl. 2003. PMID: 12797675 Review.

6

Decision analysis and economic modelling: a primer.

Inadomi JM. Inadomi JM. Eur J Gastroenterol Hepatol. 2004 Jun;16(6):535-42. doi: 10.1097/00042737-200406000-00005. Eur J Gastroenterol Hepatol. 2004. PMID: 15167154 Review.

7

A cost-utility analysis of secondary prophylaxis for variceal hemorrhage.

Rubenstein JH, Eisen GM, Inadomi JM. Rubenstein JH, et al. Among authors: inadomi jm. Am J Gastroenterol. 2004 Jul;99(7):1274-88. doi: 10.1111/j.1572-0241.2004.04153.x. Am J Gastroenterol. 2004. PMID: 15233665 Free article.

8

Dysphagia drives doctors to diagnose a disease: pitfalls in interpreting observational studies.

Rubenstein JH, Inadomi JM. Rubenstein JH, et al. Among authors: inadomi jm. Gastrointest Endosc. 2005 Jun;61(7):809-11. doi: 10.1016/s0016-5107(05)00544-4. Gastrointest Endosc. 2005. PMID: 15933680 No abstract available.

9

The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma.

Rubenstein JH, Vakil N, Inadomi JM. Rubenstein JH, et al. Among authors: inadomi jm. Aliment Pharmacol Ther. 2005 Jul 15;22(2):135-46. doi: 10.1111/j.1365-2036.2005.02536.x. Aliment Pharmacol Ther. 2005. PMID: 16011672 Free article.

10

Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia.

Rubenstein JH, Davis J, Marrero JA, Inadomi JM. Rubenstein JH, et al. Among authors: inadomi jm. Aliment Pharmacol Ther. 2005 Aug 1;22(3):267-71. doi: 10.1111/j.1365-2036.2005.02544.x. Aliment Pharmacol Ther. 2005. PMID: 16091065 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

232 results

Search Page